Clinical Trial Update: Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

View source ↗

Summary

A clinical trial is evaluating biomarkers PD-L1, tumor mutational burden, MSI, and ctDNA to predict and monitor response to immunotherapy in metastatic cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Liver Cancer
• Non-small Cell Lung Cancer

Snippet

Sponsor: Gene Solutions | Conditions: Non Small Cell Lung Cancer, Breast Cancer | Status: RECRUITING